The trial proposed is a single arm phase II treatment protocol designed to examine engraftment, toxicity, graft-versus-host disease, and ultimate disease-free survival following a novel cytoreductive regimen including busulfan, cyclophosphamide and fludarabine and anti-thymocyte globulin (ATG- a non-chemotherapy drug whose role is to kill your immune system) for the treatment of patients with Fanconi anemia who have severe aplastic anemia (SAA), or myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), lacking HLA-genotypically identical donors using stem cell transplants derived from (1) HLA-compatible unrelated donors or (2) HLA haplotype-mismatched related donors.
We are currently recruiting patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
1
Donor Peripheral blood progenitor cells will use CD34+ selection with the use of the CliniMACs device
Chemotherapy administered as a part of the HSCT conditioning regimen.
Chemotherapy administered as a part of the HSCT conditioning regimen.
Chemotherapy administered as a part of the HSCT conditioning regimen.
Chemotherapy administered as a part of the HSCT conditioning regimen.
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
To measure the incidence and quality of engraftment and hematopoietic reconstitution.
To measure the incidence and quality of engraftment and hematopoietic reconstitution.
Time frame: 1, 3, 6 and 12 months post transplant date
The incidence of early transplant related mortality and incidence and severity of acute and chronic GVHD
The incidence of early transplant related mortality and incidence and severity of acute and chronic GVHD
Time frame: weekly for the first 30 days and then 3, 6, and 12 months post transplant date
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.